Skip to main content
OpenTrials
Completed

NCT Number: NCT03312478

Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes

Primary Objective:

To measure the association between a parental history of diabetes and the odds of an offspring being Type 1 diabetics.

Secondary Objectives:

* To document the profile of Type 1 diabetes patients. * To document the glycemic parameters (Fasting blood glucose [FBG] and glycosylated hemoglobin [HbA1c]) of Type 1 diabetes. * To capture the current therapeutic management.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–20 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

National Institute of Child Health

Karachi, Sindh, 75510, Pakistan

About this study

The overall duration of this study is expected to be 12 months. The recruitment period for a given center will be four months following site initiation of that center. telephonic follow-up for all the patients shall be conducted after 15 days ± 5 days.

*Each patient (cases as well as controls) will be required to undergo laboratory tests for insulin autoantibodies and hemoglobin A1c tests. Both the tests will be conducted through centralized laboratories for all recruited patients.

Since the result of insulin auto-antibodies test is one of the inclusion criteria, it is mandatory for all patients to undergo this test, and detailed information for the same has been included in the informed consent form.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

for Cases

  • Age ≥ 2 years and ≤ 20 years.
  • Type 1 diabetes mellitus (T1DM) at any stage of life assessed as:
  • Insulin initiated within one year of diagnosis.
  • One or more islet autoantibodies (insulin auto-antibodies [IAA], glutamic acid decarboxylase (GAD), or IA2) positive at the time of enrolment. The laboratory value for IAA ≥ 2.4 units/mL, ≥ 10 IU/mL for IA2 and ≥ 5 IU/mL for anti-GAD to be labelled as positive.
  • Consenting to participate in the study or care giver ready to sign data release consent if the patient is less than legal limit which is 18 years of age.

Inclusion criteria

for Controls

  • Age ≥ 2 years and ≤ 20 years. Every control will be matched for a specific patient within ± two years of age.
  • Non diabetic.
  • All islet autoantibodies negative at the time of enrolment (IAA, GAD, or IA2). The laboratory value for IAA ≤ 2.4 units/mL, ≤ 10 IU/mL for IA2, and ≤ 5 IU/mL for anti-GAD to be labelled as negative.
  • Consenting to participate in the study or care giver ready to sign data release consent if the patient is less than 18 years of age.

Exclusion criteria

Exclusion criteria

for Cases:

  • Age ≤ 2 years and >20 years.
  • Patients with any other pre-existing auto-immune disease.
  • Gestational Diabetes.
  • Pregnant Woman.

Exclusion criteria

for Controls:

  • Age ≤ 2 years and > 20 years.
  • Patient with history of Type 1 (T1) and Type 2 Diabetes Mellitus (T2DM).
  • History of T1 and T2DM in siblings.
  • Gestational Diabetes.
  • Pregnant Woman.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

Blood draw for insulin auto-anti body tests*

Drug

Pharmaceutical form: N/A

Route of administration: N/A

Primary outcomes

  1. Odds of Type 1 Diabetes Mellitus child having a diabetic parent

    Time frame: 12 months

    Odds ratio will be used to calculate and measure disease frequency from dichotomous categorical variables

Secondary outcomes

  1. Characterization of this population by gender

    Time frame: 12 months

    Categorical variables (gender) will be presented as proportions

  2. Characterization of this population by age

    Time frame: 12 months

    Categorical variables (age) will be presented as proportions

  3. Characterization of this population by socio-economic profile

    Time frame: 12 months

    Categorical variables (socio-economic profile) will be presented as proportions

  4. Means of HbA1c in Type 1 diabetes mellitus (T1DM) patients

    Time frame: 12 months

    Mean HbA1c

  5. Standard deviation of HbA1c in T1DM patients

    Time frame: 12 months

    Standard deviation of HbA1c

  6. Distribution of prescribed therapies by type of insulin to T1DM patients

    Time frame: 12 months

    Distribution of prescribed therapies by type of insulin will be presented as proportions

  7. Means of fasting blood glucose (FBG) in T1DM patients

    Time frame: 12 months

    Mean Fasting Blood Glucose

  8. Standard deviation of FBG in T1DM patients

    Time frame: 12 months

    Standard deviation of FBG

  9. Duration of diabetes in parent

    Time frame: 12 months

    Mean duration of diabetes in parent

  10. Mean duration of diabetes in parent

    Time frame: 12 months

    Standard deviation of duration of diabetes in parent

  11. Characterization of family history of diabetes

    Time frame: 12 months

    Categorical variables will be measured as proportions

  12. Characterization of frequency of consultation

    Time frame: 12 months

    Number of consultations per month

  13. Characterization of diabetes education

    Time frame: 12 months

    Number of sessions per month

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

To Evaluate the Association Between Type 1 Diabetes Mellitus (T1DM) in Offspring With Positive Parental History of Diabetes

Acronym: SHINE

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Oct 17, 2017
Registry last updated
Apr 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.